UCB SA (UCBJY)
OTCMKTS
· Delayed Price · Currency is USD
150.71
+4.93 (3.38%)
At close: Mar 9, 2026
UCB SA Employees
UCB SA had 9,378 employees as of December 31, 2024. The number of employees increased by 295 or 3.25% compared to the previous year.
Employees
9,378
Change (1Y)
295
Growth (1Y)
3.25%
Revenue / Employee
$930,761
Profits / Employee
$187,331
Market Cap
56.58B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| CytoDyn | 13 |
| Vaxart | 105 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
| ZIVO Bioscience | 7 |
UCB SA News
- 5 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 9 days ago - UCB SA (UCBJY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 months ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire
- 7 months ago - UCB SA (UCBJF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
- 1 year ago - UCB SA (UCBJF) Q2 2024 Earnings Call Transcript - Seeking Alpha